Chronic Therapy With Sucroferric Oxyhydroxide Does Not Affect Iron And Anemia Markers In Dialysis Patients

Georgios Lioulios,Stangou Maria, Minasidis Ilias, Andreas Vainas, Pantelis Sarafidis,Ioannis Tsouchnikas, Danae Faitatzidou,Aikaterini Papagianni

BLOOD PURIFICATION(2019)

引用 5|浏览21
暂无评分
摘要
Introduction:Sucroferric oxyhydroxide (SOH) is an iron-based phosphate binder (PB), and its use has been widely expanded since its initial approval in 2014. Based on the existing data, however, it remains yet unclear whether its long-term administration is followed by iron overload in dialysis patients. The purpose of this observational study was to evaluate the longstanding effects of SOH on the anemia and iron indices in patients on dialysis.Methods:A total of 110 patients from 3 dialysis centers were included in the study; 49 were under chronic treatment with SOH (cohort A), while 61 were either receiving other PB or no treatment for hyperphosphatemia (cohort B). We initially compared the hematologic profile of patients in 2 cohorts (phase I), and subsequently, we evaluated modifications of the above parameters in the SOH treated patients over a period of 6 months (phase II).Results:There were no statistically significant differences between 2 cohorts in terms of hemoglobin (Hb; 11.4 +/- 1.3 vs. 11.6 +/- 0.9 g/dL,p= 0.375), ferritin (473 +/- 230 vs. 436 +/- 235 ng/mL,p= 0.419) and transferrin saturation (TSAT;26.6 +/- 13.2 vs. 26.5 +/- 10.6%,p= 0.675), serum phosphate concentration (4.57 +/- 1.05 vs. 4.3 +/- 0.96 mg/dL,p= ns), and intact PTH (286 +/- 313 vs. 239 +/- 296 pg/mL,p= ns). Marginally, but significantly higher calcium levels were found in cohort A compared to cohort B (9.18 +/- 0.58 vs. 8.9 +/- 0.51 mg/dL, respectively,p= 0.008). In phase II, no significant changes were observed in hematological parameters after a 6-month treatment with SOH (Hb: from 11.5 +/- 1.1 to 11.4 +/- 1.3 g/dL,p= 0.4, serum ferritin levels: from 475 +/- 264 to 473 +/- 230 ng/mL,p= 0.951, TSAT: from 26.5 +/- 16.7 to 26.6 +/- 13.2%,p= 0.933). There were also no significant changes in the administration of iron supplements or erythropoietin dose during this period.Conclusions:SOH is an effective PB, and its long-term use is not complicated by iron overload.
更多
查看译文
关键词
Dialysis,Phosphate binder,End-stage renal disease,Anemia,Sucroferric oxyhydroxide
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要